Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial of obeticholic acid in patients with secondary bile acid diarrhoea (sBAD) due to Crohn's disease

X
Trial Profile

Phase IIb trial of obeticholic acid in patients with secondary bile acid diarrhoea (sBAD) due to Crohn's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Crohn's disease; Diarrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2014 New trial record
    • 09 Jan 2014 Intercept Pharmaceuticals expects to initiate this trial in the second half of 2014, according to a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top